Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Gain Therapeutics, Inc. (GANX) had Return on Tangible Equity of -157.17% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-5.81M |
|
-- |
|
-- |
|
$5.09M |
|
$-5.09M |
|
$-0.58M |
|
$-5.67M |
|
$-5.67M |
|
$-5.81M |
|
$-5.81M |
|
$-5.81M |
|
$-5.81M |
|
$-5.09M |
|
$-5.07M |
|
30.34M |
|
30.34M |
|
$-0.19 |
|
$-0.19 |
|
| Balance Sheet Financials | |
$9.31M |
|
$0.10M |
|
$0.53M |
|
$9.83M |
|
$5.20M |
|
$0.33M |
|
$0.94M |
|
$6.14M |
|
$3.70M |
|
$3.70M |
|
$3.70M |
|
30.77M |
|
| Cash Flow Statement Financials | |
$-8.92M |
|
-- |
|
$4.86M |
|
$10.42M |
|
$6.73M |
|
$-3.69M |
|
$0.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.79 |
|
-- |
|
-- |
|
0.08 |
|
0.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.92M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-157.17% |
|
|
Return on Tangible Equity |
-157.17% |
-59.07% |
|
-144.45% |
|
$0.12 |
|
$-0.29 |
|
$-0.29 |
|